Scarica l'app Stockscreener
1.26
7.69%
0.09
Dopo l'orario di chiusura:
1.25
-0.01
-0.79%
Precedente Chiudi:
$1.17
Aprire:
$1.13
Volume 24 ore:
256.39K
Relative Volume:
0.73
Capitalizzazione di mercato:
$78.95M
Reddito:
-
Utile/perdita netta:
$-64.20M
Rapporto P/E:
-0.586
EPS:
-2.15
Flusso di cassa netto:
$57,000
1 W Prestazione:
+3.28%
1M Prestazione:
-14.29%
6M Prestazione:
-76.05%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.05
$1.26
Intervallo di 1 settimana:
$1.05
$1.31
Portata 52W:
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Nome
Climb Bio Inc
Settore
Industria
Telefono
1-866-857-2596
Indirizzo
20 WILLIAM STREET, WELLESLEY HILLS
Confronta CLYM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.26 | 78.95M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | Leerink Partners | Outperform |
Climb Bio Inc Borsa (CLYM) Ultime notizie
CLYM stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
Climb Bio expands board with two new directors - Investing.com Australia
Climb Bio expands board with two new directors By Investing.com - Investing.com Canada
Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board - TipRanks
Climb Bio Expands Board with New Director Appointments - TipRanks
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times
Biotech Leaders Join Climb Bio Board: 11 Successful Drug Launches Experience - Stock Titan
CLYM stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
What is Leerink Partnrs’ Estimate for Climb Bio Q2 Earnings? - Defense World
Bioplastics And Biopolymers Market Key Drivers, Opportunities and Trends | Exactitude Consultancy - Yahoo Finance
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Healthcare Spotlight: Climb Bio Takes Center Stage at Major Needham Conference - Stock Titan
Climb Bio Advances Clinical Trials and Expands Pipeline - TipRanks
Can you use home equity to pay for long-term care? - Yahoo Finance
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report - Yahoo Finance
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Downloadable Quarterly Update - Yahoo Finance
Citigroup (C) Could Be a Great Choice - Yahoo Finance
China deals look beyond cancer - BioCentury
Climb Bio Files For Offering Of Common Stock Up To $22.4 MillionSEC Filing - MarketScreener
Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates - Marketscreener.com
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates - Yahoo
Conagra to close Michigan plant, impacting 85 jobs - Yahoo Finance
Exclusive: BlackRock expands blockchain-based money market to Solana, in tie-up with startup Securitize - Yahoo Finance
Climb Bio Secures 3-Year Cash Runway with $212M, Advances Multi-Disease Pipeline - Stock Titan
Climb bio SVP Emily Pimblett sells shares worth $1,570 By Investing.com - Investing.com South Africa
Climb bio SVP Emily Pimblett sells shares worth $1,570 - Investing.com India
Why Are Jabil (JBL) Shares Soaring Today - Yahoo Finance
Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report - Yahoo Finance
Climb Bio (CLYM) Expected to Announce Earnings on Thursday - Defense World
Gossamer Bio shares rise on Q4 earnings beat By Investing.com - Investing.com South Africa
Gossamer Bio shares rise on Q4 earnings beat - Investing.com India
Bio-Key International Inc (BKYI): Major Improvements, Worth A Look - Stocks Register
Sugar Prices Climb on the Prospects for Lower Global Sugar Production - The Globe and Mail
Sugar Prices Climb on the Outlook for Small Sugar Output in India - The Globe and Mail
CLYM stock touches 52-week low at $1.29 amid market challenges - Investing.com Australia
CLYM stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa
(PDF) Research on Dynamics and Stability in the Stairs-Climbing of a Tracked Mobile Robot - ResearchGate
Stocks of Codexis Inc (CDXS) are poised to climb above their peers - SETE News
Mineralys shares climb on study data for blood pressure drug - BioPharma Dive
First-class stamp price climbs to £1.70 in ‘blow to consumers’ - Yahoo Finance UK
Global stocks climb as pound and euro hit four-month high against US dollar - Yahoo Finance UK
Climb Bio (NASDAQ:CLYM) Shares Down 6.9% – Should You Sell? - Defense World
FTSE 100 and US stocks climb higher as US inflation report meets expectations - Yahoo Finance UK
Coupang’s shares climb after profit surges in competitive market - Fortune
CLYM stock touches 52-week low at $1.4 amid market challenges - Investing.com Australia
CLYM stock touches 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Plug To Announce 2024 Fourth Quarter and Year-End Results - The Manila Times
Climb Bio to Present at Upcoming Investor Conferences - The Bakersfield Californian
Climb Bio Sets Investor Calendar: Key March Presentations at Major Healthcare Conferences - StockTitan
After leaving FDA, Cavazzoni joins Pfizer as CMO - BioCentury
Climb Bio Inc Azioni (CLYM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):